tiprankstipranks
Avenue announces last patient last visit in Phase 1b/2a trial of AJ201
PremiumThe FlyAvenue announces last patient last visit in Phase 1b/2a trial of AJ201
8M ago
Avenue Therapeutics reports Q1 EPS ($15.40) vs ($101.57) last year
Premium
The Fly
Avenue Therapeutics reports Q1 EPS ($15.40) vs ($101.57) last year
8M ago
Avenue Therapeutics files to sell 1.42M shares of common stock for holders
Premium
The Fly
Avenue Therapeutics files to sell 1.42M shares of common stock for holders
8M ago
Navigating the Maze: Avenue Therapeutics Grapples with Regulatory Hurdles for IV Tramadol
PremiumCompany AnnouncementsNavigating the Maze: Avenue Therapeutics Grapples with Regulatory Hurdles for IV Tramadol
10M ago
Avenue Therapeutics granted extension for Nasdaq compliance
Premium
The Fly
Avenue Therapeutics granted extension for Nasdaq compliance
10M ago
Avenue Therapeutics to presents BAER-101 preclinical data at ASENT meeting
Premium
The Fly
Avenue Therapeutics to presents BAER-101 preclinical data at ASENT meeting
10M ago
Avenue Therapeutics enters warrant exercise transactions for $5M in procceeds
PremiumThe FlyAvenue Therapeutics enters warrant exercise transactions for $5M in procceeds
1y ago
Avenue Therapeutics reaches final agreement with FDA for Phase 3 safety study
Premium
The Fly
Avenue Therapeutics reaches final agreement with FDA for Phase 3 safety study
1y ago
Avenue announces completion of enrollment in Phase 1b/2a trial of AJ201
Premium
The Fly
Avenue announces completion of enrollment in Phase 1b/2a trial of AJ201
1y ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100